How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

哥德尔智能体框架实现了任务策略和元学习算法的同步演化，使多智能体能够探索更广阔的架构设计空间。该研究证明了哥德尔智能体能够通过自指进行递归自我改进，大幅提升复杂推理任务的性能，为突破现有多智能体设计的性能天花板提供了一种全新的范式。而当AI掌握了自我修改的能力，传统基于预设规则的对齐将彻底失效。 我们必须学会在复杂适应系统的层面，以进化的视角去理解和约束AI。

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

“Of all ideas I have introduced to children, recursion stands out as the one idea that is particularly able to evoke an excited response.” — Seymour Papert, Mindstorms You may not know it, but our ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...